Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."

"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."

"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."

"Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen."